Who We Are
Abii is an early-stage deeptech startup based at DTU Skylab, Kongens Lyngby, Denmark. We are building the next generation of recombinant antibody production.
Our Mission
The recombinant antibody market is large, growing, and structurally underserved at the intersection of sequence-defined reproducibility and format flexibility. Major players compete on catalogue size and brand recognition. Abii competes on a different axis: the same sequence-validated recombinant standard to deliver the same binder in the format the researcher needs, when they need it.
The Abii platform treats the binder as a permanent asset and the constant region as a configurable parameter. For a research community that has spent decades struggling with antibody reproducibility, that is a meaningful offer.
- Founded2026
- LocationDTU Skylab, Kongens Lyngby, Denmark
- StageEarly-stage deeptech
- First pilotSigned Feb 2026 - CEU San Pablo
The Founders
Antonio Asensio Martín
Antonio is completing his MSc in Engineering in Biotechnology. His background spans molecular biology, genetic engineering, and recombinant protein production. He is responsible for the design of the modular expression system, the landing pad strategy, and the experimental validation roadmap.
Sara Izpura Luis
Sara holds a Master's degree in Advanced Therapies and works as a Research Assistant at Institute of Molecular Medicine (IMMA). Her scientific background in gene and cell therapies gives her a deep understanding of the regulatory and technical landscape for biological products. Sara leads the commercial and strategic development of Abii.
Two additional co-founders, one with deep expertise in antibody biology and one with business development experience, are identified and will join upon securing initial financing.
Want to collaborate?
Whether you are a researcher, potential co-founder, or investor, we would love to hear from you.
Get in Touch